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Abstract: 
Food allergy is a major public health issue with growing prevalence in the urbanized world 
and significant impact on the lives of allergic patients and their families. Research into the risk 
factors that have contributed to this increase and their underlying immune mechanisms could 
lead us to definitive ways for treatment and prevention of food allergy. For the time being, 
introduction of peanut and other allergenic foods in the diet at the time of weaning seems to 
be an effective way to prevent the development of food allergy. Improved diagnosis and 
appropriate management and support of food allergic patients are central to patient care 
with food immunotherapy and biologicals making the transition to clinical practice. With the 
new available treatments it is becoming increasingly important to include patient’s and family 
preferences to provide a management plan tailored to their needs. 
 




Impact of food allergy 
Food allergy (FA) affects about 8% of children in the Western countries and seems to be rising 
in other parts of the world, particularly in urban rather than rural areas of countries such as 
Vietnam and South Africa, and other parts of Asia and Africa1-4. The prevalence of FA has 
increased over the recent decades, as have the number of hospitalizations for food-induced 
anaphylaxis, following what seems to be the “second wave of the allergy epidemic” after the 
rise in prevalence of asthma and respiratory allergy in previous decades5-7. Pouessel et al8 
have shown that foods caused 37% of cases of ICU admissions for anaphylaxis and 79% of 
recurrent anaphylaxis. Self-reported FA is even more common with an often 
underappreciated impact1. Gupta et al1 report that about 40% of children report multiple 
food allergies, often severe food allergies, and carry and adrenaline auto-injector. In Western 
countries, such as the US and the UK, FA affects disproportionally children from ethnic 
minorities, such as children of Afro-Caribbean descent1,9,10. Whether this has to do with 
genetic predisposition in face of environmental factors related to the modern life-style or 
whether the cultural background, the history of inequality and different access to healthcare 
also play a role, it is unclear10,11. The  three-fold higher risk of peanut and other food allergies 
in infants born in Australia to Asian born parents compared with the risk of peanut allergy in 
infants born to Australian-born parents reinforced this discrepancy reinforce the rapidity with 
which these changes occur and the importance of gene-environment interactions, that need 
to be further explored12.  
There is no curative treatment for FA and the mainstay of management is allergen avoidance. 
Emergency medication needs to be made available to patients to enable them to treat acute 
allergic reactions that may result from accidental exposure to the culprit allergens, which are 
unfortunately common13. Allergen avoidance imposes dietary restrictions, with potential 
nutritional consequences and can lead to food insecurity14-16. Eighty six per cent of mothers 
of children with suspected FA avoid foods on their own initiative17. Goldberg et al16 have 
recently shown that milk allergic young adults have reduced bone mineral density and that 
low calcium intake, asthma and weight constitute independent risk factors. FA can also result 
in an impairment of quality of life and mental health of children and their families17-20. For 
instance, mothers of children with suspected FA have higher state and trait anxiety scores 
than healthy controls17 and about 50% of children and teenagers with FA experience 
bullying18. FA can also impact negatively on the costs, not only related to the healthcare but 
also the indirect costs, for instance related to school and work absences, and the financial 
burden on the families themselves, resulting for example from the need to spend more time 
shopping and  to find alternative foods, that are often more expensive. All these factors 
account for additional negative impact on the lives of children with FA and their families, that 
goes beyond the state of hypersensitivity to the culprit allergens, and underscore the 
importance of an accurate diagnosis and the search for specific treatments for FA.  
 
Epidemiology  
The prevalence of IgE-mediated FA is highest in infancy and early childhood, driven by a 
relatively high prevalence of egg and cow’s milk allergy that often resolves later in childhood. 
By contrast, peanut and tree nut allergy, which also typically present in infancy, are less likely 
to resolve and therefore predominate in later childhood21. Marked differences in the 
prevalence of FA between countries have been noted for multiple foods, although data from 
some countries remains sparse 22-26. More recent studies have shown that large differences 
in FA prevalence can exist even within individual countries, with some of this difference driven 
by a lower prevalence in rural areas compared with urban areas4,27,28. Reasons for these 
differences are largely speculative, with differences in the prevalence of the risk factors 
described below potentially playing a role.  
The strongest known risk factor for FA is probably eczema, particularly eczema which starts 
early in life and is more severe27,28. This finding has been noted consistently across studies in 
both population-based studies and in allergy clinics for many years; however, the mechanism 
driving this association remains unclear. It has been hypothesised that a damaged skin barrier 
resulting from eczema may allow the absorption of food allergens through the skin leading to 
food sensitisation and allergy, in the absence of pre-existing oral tolerance to those foods29. 
Alternative explanations include the existence of shared genetic or environmental risk factors 
leading to an increased risk of both eczema and FA.  
There has been strong interest in identifying factors that can be modified to prevent FA. Both 
observational studies and randomised controlled trials have investigated the association 
between FA and factors including vitamin supplements, fish oil, probiotics and timing of 
introduction of allergenic foods. These are described further below in the FA prevention 
section. Other factors that have been associated with risk of FA include factors potentially 
associated with increased microbial exposure such as pet dogs and older siblings30,31.  
 
 
Mechanisms and pathophysiology  
T cells are central coordinators of the immune response to food allergens, namely the 
production of antibodies by B cells, and understanding the underlying immune mechanism 
can help us identify targets for treatment and other interventions to prevent and reduce the 
impact of FA. Using mass cytometry for immunoprofiling of infants, Neeland et al32 described 
cellular fingerprints associated with peanut allergy and tolerance amongst IgE sensitised 
infants. Peanut allergic infants had increased frequency of CD19hiHLA-DRhi activated B cells 
and of peanut-specific memory CD4+ T cells as well as overproduction of TNFalpha whereas 
peanut sensitised tolerant infants had reduced frequency of CD4+ naïve T cells and an 
increased frequency of plasmacytoid dendritic cells. Following the description of the new 
subset of Th2 cells typical of highly allergic patients, the TH2A cells, and that decreased 
following allergen-specific immunotherapy by Wambre et al33, Chiang et al34 found highly 
differentiated Th2 cells in the peripheral blood of peanut allergic patients that were resistant 
to the counter effect induced by regulatory T cells whereas healthy controls did not have 
detectable T cell responses to peanut. A stability of T regulatory response was reported by 
Weissler et al35 in both allergic and non-allergic subjects, with a Th2 and Th1-skewed peanut 
response detected in sensitised and non-sensitised individuals, respectively. However, 
Pellerin et al found that Tr1 cells were functionally impaired in peanut allergic compared to 
healthy controls. Ruiter et al36 studied the TCR repertoire of CD154+CD4+ memory T cells and 
found strong convergent selection of peanut-specific clones that were more numerous 
among effector T cells of peanut allergic patients, with an imbalance between effector and 
regulatory T cells. The more reactive patients had a more diverse and polarised Th2 effector 
phenotype with the expression of Th2 cytokines correlating with peanut-specific IgE levels.  
Recently, new studies have shed light on the role of antibodies in allergy and tolerance and 
on the still puzzling discrepancy between the presence of allergen-specific IgE and clinical 
reactivity to foods. For instance, a new subset of T follicular helper cell has been identified in 
the germinal centre and designated Tfh13 cells37. Tfh13 cells are characterised by a distinct 
transcription factor profile, that includes BCL6 and GATA-3, and by the production of IL-4 and 
Il-13. Tfh13 result in high affinity IgE production that is able to induce anaphylaxis to allergens. 
This high affinity IgE is most likely a result of indirect isotype switching from IgG1+ to IgE+ B 
cells. Contrary to IgG and IgE that depend on germinal centres and Tfh cells, IgA seems to 
follow an independent mechanism that requires T cells and CD40-ligand but is independent 
of germinal centres, Tfh and T follicular regulatory cells38. Interestingly, Hoh et al39 have 
shown that the class switch recombination from IgG to IgE and the somatic hypermutation 
that lead to increased affinity for allergens could develop in the gut of peanut allergic 
individuals, underscoring the importance of gut-associated lymphoid tissue in FA.  
Apart from intrinsic characteristics of IgE, like affinity for allergens, post-translational 
modifications such as glycosylation can have an impact in the ability of IgE to cause effector 
cell activation and consequently allergic reactions. In a recent study, Shade et al40 reported 
that total IgE from peanut allergic had higher sialic acid content compared to non-atopic 
subjects and that desialylation of IgE reduced effector cell degranulation and consequent 
anaphylaxis, raising a new possibility for intervention in treating allergic disease, including FA.  
These differences in T and B cell responses and antibody profile modulate the effector cell 
response. Hemmings et al41 showed that Ara h 2-specific IgE induced greater inhibition of IgE 
binding and greater mast cell degranulation than Ara h 6, confirming that despite sequence 
and structural similarities between Ara h 2 and Ara h 6 and the fact that both are major 
allergens in peanut, Ara h 2 is the dominant allergen. Effector cell response to allergen can 
support the identification of phenotypes of food allergic patients that may deserve different 
type of follow up and may have indication for specific treatments, such as allergen-specific 
immunotherapy or biologics. Patil et al42 assessed basophil responses to Ara h 2 in peanut 
allergic patients at baseline and at different time points during peanut oral immunotherapy 
(OIT). Basophil sensitivity, defined by the concentration at which basophils reacted, after 3 
months of OIT, could distinguish the patients who responded had sustained unresponsiveness 
at the end of the trial from the patients who had transient desensitisation and whose basophil 
response to Ara h 2 rebounded after stopping OIT.  
To conclude, understanding the immune mechanisms underlying FA and oral tolerance is key 
to improve diagnostics and the care for patients and their families and identify targets for a 
definitive treatment of FA. Table 1 summarizes recent new discoveries about immune 
mechanisms of FA. 
 
Diagnosis  
An accurate diagnosis of FA is essential. Correctly identifying FA is crucial for providing 
education and management strategies to mitigate the risks of a potentially life-threatening 
allergic reactions. In contrast, correctly identifying food tolerance will promote dietary 
liberation which is especially important in light of the paradigm shift encouraging early 
introduction of allergenic foods to prevent FA.43 Double-blind placebo-controlled food 
challenges remain the gold standard of FA diagnosis. However, due to the inherent risks and 
intensive resource requirements, their feasibility is limited in some clinical and research 
settings.   
Skin prick tests (SPT) and serum-specific IgE (sIgE) are routinely used in clinical practice and 
are relatively safe and inexpensive to perform. However, the conventional positive results 
(SPT ≥ 3mm or sIgE ≥ 0.35ku/l) have poor specificity to clinical FA, with approximately half of 
sensitised individuals able to tolerate the food without reaction. As increasing magnitude of 
these tests correlates to a higher risk of reaction, many studies have defined thresholds for 
these tests with 95% positive predictive value (PPV) to FA (reviewed in 44-49).  Although SPT 
and sIgE thresholds with 95% PPV to FA are routinely used to minimise the need for diagnostic 
food challenges, a proportion of children remain in the immunological grey area, that is, they 
are food sensitised but below the 95% PPV threshold. New approaches that can accurately 
diagnose FA while reducing the need for food challenges are urgently needed.  
Allergen component-resolved diagnostics (CRD) are proposed as a more accurate method of 
diagnosis, because instead of using crude allergen extracts which consist of both allergenic 
and non-allergenic components, CRD measures sIgE to individual allergen proteins. A 
systematic review comparing SPT and sIgE to whole peanut and its components concluded 
that sIgE to ara h2 had greater diagnostic accuracy compared to the other tests.47 
Furthermore, a meta-analysis of 19 studies found that while sIgE to Arah 1, 2 and 3 had high 
specificity to peanut allergy, sensitivity was highest Arah 2. The pooled sensitivity and 
specificity of Arah2 ≥ 0.35kU/L to peanut allergy was 83% (95% CI 76-89%) and 84% (95% CI 
77-88%).50 Likewise, further studies support that component resolved diagnostics offer 
greater accuracy compares to sIgE to whole allergens for hazelnut 51 and it is plausible that 
this increased accuracy applies to other foods. The major allergen components for most 
common food allergens have been isolated and research continues to identify the optimal 
cut-off points.52   
Molecular approaches to the diagnosis of FA also appear to offer greater sensitivity and 
specificity than traditional tests. The basophil activation test measures the expression of 
activation markers on the surface of basophils stimulated with food allergens and controls, 
by flow cytometry.53 In a study of 109 children, BAT demonstrated superior ability to 
discriminate between peanut allergic and sensitized- tolerant children compared to SPT, sIgE 
and sIgE to ara h2. The optimal diagnostic parameter and threshold demonstrated an 
impressive sensitivity and specificity of 98% (95% CI 87-100) and 96% (95% CI 86-100) 
respectively. BAT performed similarly well when validated in an independent sample (83% 
sensitivity and 100% specificity).54 For other allergens, BAT performed well but not necessarily 
superior to other measures. In a prospective study of 83 children with suspected tree nut 
allergy, SPT demonstrated greater sensitivity to BAT, while BAT demonstrated greater 
specificity compared to SPT; AUC was similar for both measures with the exception of 
hazelnut where BAT had greater AUC than SPT55. While the performance of BAT appears 
promising, its clinical utility may be limited because it requires live cells and flow cytometry 
equipment. BAT may therefore be more feasible in settings where it can be used in 
combination with conventional diagnostic tests. For example, performing peanut BAT as a 
second step following equivocal SPT or sIgE to Ara h2, reduced the need for OFC by 97% 
compared to the combination of SPT and sIgE to whole peanut.54  
Mast cell activation tests offer another promising approach and have the advantage over BAT 
that they use stored plasma rather than fresh whole blood. In the same sample as described 
previously for peanut BAT54 MAT performed equally well to BAT in terms of specificity, 
however the sensitivity of MAT was lower than BAT. Importantly, MAT provided definitive 
results in all cases where basophils were non-responsive.56 In a smaller study, MAT performed 
better than BAT based on AUC for the diagnosis of peanut allergy, however confidence 
intervals overlapped.57 The utility of these test has been assessed for some other common 
allergens and performs similarly well other further research is needed.58 Additionally, these 
molecular approaches may offer additional clinical utility as the results are correlated to 
reaction severity57,58, whereas SPT and sIgE are not always predictive of reaction severity59,60. 
However further work is required to inform standardisation of laboratory procedures, optimal 
test parameters and thresholds, and cost-effectiveness in different settings before these 
novel approaches are ready for routine clinical practice.53 
Despite continued advances and development of novel molecular techniques, identifying a 
definitive diagnostic test to negate the need for oral food challenges remains elusive. The 
optimal threshold requires a trade-off between false negatives false positives and this varies 
in the published literature due to heterogeneity in study sample, design, methods, regional 
characteristics, allergen extracts and laboratory procedures. Figure 1 represents a suggested 
approach to the sequential use of diagnostic tests. Identification, validation, and cost-





In absence of effective treatment, allergen avoidance and providing appropriate emergency 
medication used to be the only approach to management of food allergy (FA). 1 Avoidance of 
food allergen is onerous for patients and families and often fails with ten per cent of patients 
on average experiencing an allergic reaction per year. 2 3 4 Additionally, allergen avoidance 
inflicts multiple pressures on allergic individuals and their families, food manufacturers and 
restaurants as well as public spaces such as schools or aircrafts. 5 6 Precautionary allergen 
labelling is in general voluntary and used inconsistently across industry which is misleading 
for patients and caregivers. 2 
Providing adrenaline autoinjectors (AAI) to patients at risk of anaphylaxis encounters 
challenges related to their availability which is mostly limited to high-income countries, varied 
national regulations in prescribing and high cost. 7 When prescribed, AAI are only carried at 
all times by half of the patients 8 and mistakes in use are frequent among both patients 9 and 
medical staff. 10  
Meeting the needs of both food allergic children undergoing immunotherapy and those 
continuing strict avoidance in the same environment, e.g. school or household with two 




Just over twenty years since the first RCT showed its high efficacy 11, food immunotherapy 
(FIT) has become the first established treatment modality for food allergy (FA) which is now 
recommended by national and international guidelines. 12 13 14 High efficacy of oral FIT has 
been consistently confirmed in RCT in children with milk, egg and peanut allergy 15 while 
slightly lower desensitization rates were achieved in wheat allergy. 16 In the largest oral FIT 
study so far, the PALISADE Study, which investigated efficacy of 300 mg dose of peanut 
protein in inducing tolerance to peanut in almost 500 children ≥4 years, 67.2% of participants  
achieved the primary end point of passing 600 mg dose at the exit DBPCFC. 17 It has also been 
confirmed recently in a placebo controlled study that peanut  oral IT (POIT) significantly 
reduces the risk of reaction after accidental exposure to peanut (placebo group, 24 reactions 
in 14 patients; active group, 8 reactions in 5 patients; p<0.001). 18Nevertheless, the recent 
safety metanalysis  which looked into 12 POIT studies estimated that the risk of anaphylaxis 
while on POIT is over three times higher compared to peanut avoidance (RR, 3.12, 95% CI 
1.76-5.55) and the risk of adrenaline use is over twice as high (RR, 2.21; 95% CI 1.27-3.83). 19 
Therefore, the current focus of FIT research is orientated towards answering crucial questions 
about increasing safety of FIT by choosing well-tolerated and effective formulation, route and 
dose, adding adjuvants at the initial stage of the treatment and identifying patients most likely 
to benefit from FIT. The other main need is understanding long-term outcomes of the 
treatment. 20 21 Table 2 summarises recent developments in FIT and Figure 2 illustrates 
phenotypes of food allergy and possible outcomes of FIT. 
Despite satisfying efficacy in inducing desensitization to the culprit food, the outcome of FIT 
differs from natural outgrowing of FA. While the benefits of a margin of protection in case of 
accidental exposure and introducing certain amount of the food in regular diet are enjoyed 
during the treatment, the long term effect remains unpredictable with up to 70 per cent 
successfully desensitised individuals losing tolerance after a short period of avoidance.36 Why 
the post-IT tolerance is lost despite apparent similarities with outgrowing in immunological 
response (decrease in specific IgE concentration and raise in specific IgG4), remains unclear.37  
As  SU is not achieved by at least half of the patients, the question remains about the 
necessary frequency of consumption of the food after completion of FIT. Reassuringly, twice 
a week consumption of an egg has proven sufficient to sustain tolerance in the Spanish SEICAP 
Study. 39 In the large long-term follow up Finnish cohort of children who completed milk OIT, 
only a quarter of the children returned to milk avoidance diet during the median 6.5 yearlong 
observation period.40 Regarding ongoing peanut consumption, 64% of previous peanut IT 
participants continued to ingest peanut daily and another 25% less frequently. Unfortunately, 
allergic reactions including airway involvement were still noted even in this late stage of 
desensitization.41 With the first commercial product for peanut OIT approved by FDA in 
January 2020, FIT is likely to become more available and uniform in the coming years. 
 
Biologicals 
In FA, biological treatments have been mostly investigated in the context of facilitating FIT. In 
addition to the above mentioned FIT/anti-IgE studies which have already been completed, 
there are ongoing projects looking at use of dupilumab in combination with peanut OIT 
(Clinicaltrials.gov NCT03793608, Clinicaltrials.gov NCT03682770), combination of dupilumab 
and omalizumab in multi-food OIT (Clinicaltrials.gov NCT03679676) as well as anti-IL-33 in 
peanut OIT (Clinicaltrials.gov NCT02920021). 42 
Due to its patomechanism, eosinophilic pathway inhibition has been extensively studied in 
the treatment of EoE. 43 The use of anti-IL-5, anti-IL-13 and anti-IL-4 has been associated with 
significant reduction of histological features of EoE in three RCT. 44 45 However, there have 
been no clear clinical improvement noted. Therefore, the treatments are currently not 
routinely recommended in EoE management. 46  
It has been shown in recent mice study that inhibition of alarmins (IL-25, IL-33 and TSLP) may 
be effective in preventing FA 47 which may suggest future promising direction of biological 




Despite significant progress in identifying risk factors for FA, there is still little that can be 
recommended to prevent FA. Few of the known risk factors described above are easily 
modifiable. Furthermore, of the potentially modifiable factors tested in clinical trials to date, 
most have not been effective in preventing FA. A recent systematic review by the European 
Academy of Allergy, Clinical Immunology FA, Anaphylaxis Guidelines Group108 identified 41 
randomised controlled trials of potential FA prevention strategies in infancy and childhood. 
The vast majority of these trials showed little to no effect on preventing FA, including trials of 
dietary avoidance of food allergens, vitamin supplements (maternal and infant), fish oil, 
probiotics, prebiotics, symbiotics, and hydrolysed formulas. However, the authors also 
concluded that the evidence around most of these interventions remains very uncertain. 
Many of the trials were at risk of bias due to lack of robust diagnostic criteria, high loss to 
follow-up, potential confounding, and lack of blinding and were underpowered for the 
outcome of interest.  
Although some of the risk of FA is likely to be already established at birth, to date there are 
no known effective preventative strategies that can be applied during pregnancy. The only 
intervention that is currently widely recommended to reduce the risk of FA is timely 
introduction of peanut into the infant diet. This recommendation is primarily based on the 
results of a large, high quality randomised controlled trial in high risk infants conducted in the 
United Kingdom9 - a country with a relatively high prevalence of FA. The relevance of these 
findings to countries with a low peanut allergy prevalence is less clear109. There is also 
evidence from meta-analyses of multiple trials that early introduction of egg into the infant 
diet reduces the risk of egg allergy, although the extent of the reduction in risk appears lower 
than for peanut43.  
 
Conclusion 
FA is a major public health issue with growing prevalence in the urbanized world and 
significant impact on the lives of allergic patients and their families. Research into the risk 
factors that have contributed to this increase and their underlying mechanisms could pave 
the way to definitive ways for treatment and prevention of FA. For the time being, 
introduction of peanut and other allergenic foods in the diet at the time of weaning seems to 
be an effective way to prevent the development of FA. Improved diagnosis and appropriate 
management and support of food allergic patients is central to patient care with food 
immunotherapy and biologicals making the transition to clinical practice. With the new 
available treatments it is becoming increasingly important to include patient’s and family 




Table 1. Highlights of new discoveries about immune mechanisms of food allergy 
 
 
T cells and T follicular helper cells 
• Food allergy involves Th2-skewed response more 
than a dysregulated regulatory T cell 
population34,35.  
• The new subset of Tfh cells Tfh13 induces the 
sequential class switching from IgG1 to IgE leading 
to the production of high affinity IgE that can cause 
anaphylaxis37. 
B cells and antibodies 
• IgE class switching can happen in the gut-
associated lymphoid tissue39.  
• IgA induces tolerance through immune exclusion 
rather than active suppression and is generated via 
a separate mechanism that is independent of Tfh 
and germinal centres38. 
Basophils and mast cells 
• IgE glycosylation enhances effector cell 
degranulation40.  
• Basophil response to allergen can distinguish 
responders from non-responders as early as 3 
months into oral immunotherapy42. 
 
  
Table 2. Recent developments in food immunotherapy. 
 
Route • Safety profile of sublingual IT (SLIT) and epicutaneous IT (EPIT) 
is favourable with hardly any systemic allergic reactions 
reported; it comes however at the cost of lower efficacy. 26,27  
• In the large phase 3 study on EPIT to peanut, 35.3% of 
participants achieved predefined response rate compared to 
13.6% of children in placebo group; despite the difference 
being statistically significant, the 95% CI exceeded prespecified 
lower cut-off which means the study did not meet its primary 
end point. 28  
• The modest level of desensitization predisposes SLIT and EPIT 
for use in individuals not tolerating OIT. 27  
• Longer treatment duration may be necessary to achieve results 
comparable with OIT. 29  
 
Dose • Daily dose equivalent of one peanut and ten peanuts exert 
similar clinical and immunological effects in peanut IT in young 
children.24   
• Using lower dose of the food seems to have a favourable effect 
on safety. No use of adrenaline related to treatment was 
reported in the recent peanut OIT study in which maintenance 
peanut protein dose was established between 125 mg and 250 
mg.18   
• However, in the group of Japanese children with history of 
anaphylaxis to wheat, 31% of subjects developed mild 
anaphylaxis despite low-dose protocol (53 mg of wheat 
protein). 25 
 
Age • FIT tends to be associated with reassuring safety profile and 
higher rates of sustained unresponsiveness if started early. 24  
• In the Italian cohort of 73 infants with IgE-mediated milk allergy 
who underwent milk OIT, 97% reached the target 150 mL dose 
of milk. No patient required use of AAI at home. 30 
 
Formulation  • Well-known phenomenon of decreased allergenicity of 
thermally processed food 22 has been used in proof of concept 
FT studies.  
• The BOPI Study looked into effectiveness and safety of boiled 
peanut IT. 28% of participants presented with 1.9 episodes of 
anaphylaxis during treatment which is comparable to average 
rate of severe adverse events reported in other studies. 
• Bird et al confirmed in a small proof of concept study that baked 
egg IT led to desensitization to lightly cooked egg with no 
moderate or severe adverse events noted. 23  
• The publication of CoFAR7 project comparing baked and fresh 
egg IT is awaited [ClinicalTrials.gov Identifier: NCT01846208]. 
 
Adjuvants • Multiple adjuvant agents have been tested in the context of 
improving benefit-risk ratio in FIT, from probiotics and Chinese 
herb medicine through montelukast and antihistamines to 
biological treatments.31  
• Anti-IgE has been the most extensively studied including 
RCTs.32  
• Omalizumab allows quicker up-dosing with fewer adverse 
events without affecting immunological desensitization 
processes.31  
• However, omalizumab may potentially mask early symptoms of 
gastrointestinal disease related to FIT.33  
• Additionally, adverse events may start occurring after 




• The baseline epitope-specific antibody binding models can 
achieve even 87% accuracy in predicting SU in milk OIT.38  
• In peanut OIT, early decrease in basophil sensitivity to Ara h 2 
correlates with SU. 36 
• Higher baseline peanut-specific IgG4 to IgE ratio and lower Ara 
h 2 IgE and basophil activation responses were associated with 
sustained unresponsiveness in the POISED Study.  
  
Figures and figure legends 
 
Figure 1. Proposed use of components-specific IgE, basophil and mast cell activation tests in 
combination with conventional tests (skin prick test and specific IgE) to reduce the need for 
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Figure 2. Clinical phenotypes of food sensitized and food allergic children and possible 
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